ICU · SeaStar Medical Holding Corp
Substantial doubt about the company's ability to continue as a going concern.
“The Company believes that these conditions raise substantial doubt about its ability to continue as a going concern.”View the 10-Q filed Aug 12, 2026
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Jan 5, 2026; bars on opposite sides are not compared.
The closing range begins at the captured split on Jan 5, 2026.
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 12, 2026TL;DR. SeaStar Medical reported Q2 2026 QUELIMMUNE net revenue of $615,000, up 82% year-over-year, with the customer base expanding to 20 top children's hospitals toward a year-end goal of 25, while the NEUTRALIZE-AKI pivotal trial advanced to 223 of 339 enrolled patients with enrollment expected around year-end or Q1 2027.
- + QUELIMMUNE net revenue grew 82% year-over-year to $615,000 in Q2 2026
- + Pediatric customer base doubled to 20 of the top 50 children's hospitals, tracking to the 2026 goal of 25
- + NEUTRALIZE-AKI pivotal trial enrollment advanced to 223 of 339 patients with additional sites activated
- + CMS assigned dedicated ICD-10-PCS codes for SCD therapy, effective October 1, 2026, simplifying hospital billing
- − Q2 net loss widened to $3.7 million from $2.0 million a year ago
- − Cash on hand declined to $7.0 million at June 30, 2026 from $12.0 million at year-end 2025
- − Operating expenses more than doubled to $4.4 million in Q2 2026 from $2.1 million a year ago
- − Recent monthly enrollment of 8-12 patients is below the company's preferred pace, with trial completion pushed to year-end or Q1 2027
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ICU
this stock
SeaStar Medical Holding Corp
|
$13.79M | — | +814.1% | — | 2.5% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.40B | +13.7% | +46.2% | 30.0 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.67B | +1.2% | +20.8% | 19.6 | 2.5% |
|
ARGX
Argenx SE
|
$61.60B | +17.1% | — | — | 2.0% |
|
CSLLY
Csl Ltd
|
$57.41B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Jan 5, 2026; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ICU | +4.1% | -4.4% | +35.9% | -3.2% | — |
| SPY | -1.2% | -1.8% | +17.8% | -0.4% | +12.1% |
| vs SPY | +5.3% | -2.7% | +18.0% | -2.8% | — |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.